12/2
08:04 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/2
07:10 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
11/26
06:33 am
cccc
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
Medium
Report
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
11/25
07:00 am
cccc
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/21
05:17 pm
cccc
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
Medium
Report
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
11/6
07:00 am
cccc
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Low
Report
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
10/17
09:00 am
cccc
Precision Oncology Approaches Drive $312B Market Transformation
Medium
Report
Precision Oncology Approaches Drive $312B Market Transformation
10/17
09:00 am
cccc
Precision Oncology Approaches Drive $312B Market Transformation
Medium
Report
Precision Oncology Approaches Drive $312B Market Transformation
10/16
07:08 am
cccc
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
High
Report
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
10/1
07:00 am
cccc
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
High
Report
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
9/23
08:46 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
9/22
08:40 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $6.00 price target on the stock.
9/22
08:05 am
cccc
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
9/22
05:48 am
cccc
C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple Myeloma Presented At IMS 2025 Transcript [Seeking Alpha]
High
Report
C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple Myeloma Presented At IMS 2025 Transcript [Seeking Alpha]
9/20
11:25 am
cccc
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting [Yahoo! Finance]
High
Report
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting [Yahoo! Finance]
9/20
11:00 am
cccc
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
High
Report
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
9/18
08:05 pm
cccc
C4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline Developments [Yahoo! Finance]
Medium
Report
C4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline Developments [Yahoo! Finance]
9/18
06:43 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
9/17
08:05 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $8.00 price target on the stock.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $8.00 price target on the stock.
9/15
08:02 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Stephens from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock.
9/9
05:55 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Low
Report
C4 Therapeutics (NASDAQ:CCCC) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
9/8
09:30 am
cccc
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Low
Report
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
9/8
09:30 am
cccc
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Low
Report
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market